Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.62 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.62 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.62 |
| ▸ | METAP1 | P53582 | 2/20 | 0.53 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630276 | 0.85 | CYP24A1 (0.70) | CYP24A1CYP27A1CYP26A1CYP19A1METAP1 | |
| SCHEMBL14159089 | 0.83 | CYP24A1 (0.69) | CYP24A1CYP27A1CYP26A1CYP19A1METAP1 | |
| SCHEMBL14165623 | 0.83 | CYP24A1 (0.66) | CYP24A1CYP27A1CYP26A1CYP19A1METAP1 | |
| SCHEMBL7590283 | 0.82 | METAP1 (0.78) | CYP24A1CYP27A1CYP26A1CYP19A1METAP1 | |
| SCHEMBL8012038 | 0.82 | METAP1 (0.78) | CYP24A1CYP27A1CYP26A1CYP19A1METAP1 | |
| Hydrochloric Acid SCHEMBL10341505 | 0.81 | METAP1 (0.78) | CYP24A1CYP27A1CYP26A1CYP19A1METAP1 | |
| SCHEMBL7519184 | 0.80 | CYP24A1 (0.54) | CYP24A1CYP27A1CYP26A1CYP19A1METAP1 | |
| SCHEMBL8200552 | 0.80 | CYP24A1 (0.61) | CYP24A1CYP27A1CYP26A1CYP19A1METAP1 | |
| SCHEMBL4853888 | 0.80 | CYP24A1 (0.65) | CYP24A1CYP27A1CYP26A1CYP19A1METAP1 | |
| Iodide SCHEMBL4621278 | 0.80 | CYP24A1 (0.61) | CYP24A1CYP27A1CYP26A1CYP19A1METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | CYP24A1 2187/4885CYP27A1 1868/4885CYP26A1 2857/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | CYP24A1 1089/4885CYP27A1 336/4885CYP26A1 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.